Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02734667 · ClinicalTrials.gov registry record · NA

Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes

A NA study of Type 1 Diabetes Mellitus, sponsored by Korey Hood.

Completed
Registry status
NA
Development phase
120
Enrollment target
2
Study locations

NCT02734667 is a NA study of Type 1 Diabetes Mellitus that has completed, run by Korey Hood. The registered enrollment target is 120 participants, below the 139-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (14% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02734667, a NA study of Type 1 Diabetes Mellitus, has completed, sponsored by Korey Hood.

COMPLETED
Registry status
NA
Development phase
120 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to learn about the impact of continuous glucose monitoring (CGM) on families with newly diagnosed children with type 1 diabetes (T1D). The investigators hope to learn about how continuous glucose monitoring affects glycemic variables and diabetes-related distress.

Conditions Studied

Interventions

  • DEVICE CGM at diagnosis of T1D

Study Locations (2)

California

  • Stanford University - Stanford

Colorado

  • University of Colorado - Aurora

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2016-02
Est. Completion 2020-02
Phase NA

Sponsor

Korey Hood

1 total trials

What the Registry Record Tells You About NCT02734667

The ClinicalTrials.gov registry entry for NCT02734667 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (14% lower). The listed sponsor is Korey Hood, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which CGM at diagnosis of T1D is the first listed.

NCT02734667 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Colorado.

Frequently Asked Questions

What is clinical trial NCT02734667 about?

NCT02734667 is a clinical study titled "Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes". The purpose of this study is to learn about the impact of continuous glucose monitoring (CGM) on families with newly diagnosed children with type 1 diabetes (T1D). The investigators hope to learn about how continuous glucose monitoring affects glycemic variables and diabetes-related distress.

What is the current status of trial NCT02734667?

This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2016-02. Estimated completion is 2020-02.

What conditions does trial NCT02734667 study?

This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.

What interventions are being tested in trial NCT02734667?

The interventions under investigation include: CGM at diagnosis of T1D (DEVICE).

Who is sponsoring clinical trial NCT02734667?

This trial is sponsored by Korey Hood, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02734667 being conducted?

This trial has 2 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.